• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减轻发展中世界日益加重的心血管疾病负担。

Reducing the growing burden of cardiovascular disease in the developing world.

作者信息

Gaziano Thomas A

机构信息

Division of Cardiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Health Aff (Millwood). 2007 Jan-Feb;26(1):13-24. doi: 10.1377/hlthaff.26.1.13.

DOI:10.1377/hlthaff.26.1.13
PMID:17211010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2365905/
Abstract

Cardiovascular disease (CVD) has become the number-one cause of death in the developing world. This epidemic has the potential to place a large social and economic burden on developing countries, where CVD tends to strike those in their prime working years. Since resources for managing CVD are limited, it is important that interventions be guided by cost-effectiveness results for low- and middle-income countries. Despite the burden, cost-effective strategies exist at the population and individual levels for reducing CVD. Integral to all personal intervention strategies is an adequate assessment of the underlying risk of disease.

摘要

心血管疾病(CVD)已成为发展中世界的首要死因。这种流行病有可能给发展中国家带来巨大的社会和经济负担,在这些国家,心血管疾病往往侵袭处于黄金工作年龄的人群。由于管理心血管疾病的资源有限,重要的是干预措施应以低收入和中等收入国家的成本效益结果为指导。尽管存在负担,但在人群和个体层面都有具有成本效益的策略来降低心血管疾病。所有个人干预策略的核心是对潜在疾病风险进行充分评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da7/2365905/fc77dd6b7ed9/nihms43250f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da7/2365905/37b7bfe8ab85/nihms43250f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da7/2365905/fc77dd6b7ed9/nihms43250f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da7/2365905/37b7bfe8ab85/nihms43250f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da7/2365905/fc77dd6b7ed9/nihms43250f2.jpg

相似文献

1
Reducing the growing burden of cardiovascular disease in the developing world.减轻发展中世界日益加重的心血管疾病负担。
Health Aff (Millwood). 2007 Jan-Feb;26(1):13-24. doi: 10.1377/hlthaff.26.1.13.
2
Reducing the global burden of cardiovascular disease: the role of risk factors.减轻全球心血管疾病负担:风险因素的作用。
Prev Cardiol. 2002 Fall;5(4):188-99. doi: 10.1111/j.1520-037x.2002.00564.x.
3
Time for results: a better way to reduce cardiovascular risk.等待结果的时间:降低心血管风险的更好方法。
Adv Nurse Pract. 2002 Apr;10(4):34-41; quiz 42-3.
4
The global burden of cardiovascular disease.心血管疾病的全球负担。
Eur J Cardiovasc Nurs. 2011 Jul;10 Suppl 2:S5-13. doi: 10.1016/S1474-5151(11)00111-3.
5
Risk factors for cardiovascular disease in Canada.加拿大心血管疾病的风险因素。
Can J Cardiol. 2003 Oct;19(11):1249-59.
6
Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.新的治疗理念:发展中国家心血管疾病的流行:全球影响。
Eur Heart J. 2010 Mar;31(6):642-8. doi: 10.1093/eurheartj/ehq030. Epub 2010 Feb 22.
7
World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic.2002年世界心脏日:心血管疾病的全球负担——应对新出现的全球流行病
Circulation. 2002 Sep 24;106(13):1602-5. doi: 10.1161/01.cir.0000035036.22612.2b.
8
Challenges and opportunities for cardiovascular disease prevention.心血管疾病预防的挑战与机遇。
Am J Med. 2011 Feb;124(2):95-102. doi: 10.1016/j.amjmed.2010.08.015.
9
The global epidemiology of heart failure.心力衰竭的全球流行病学。
Med Clin North Am. 2004 Sep;88(5):1135-43, ix. doi: 10.1016/j.mcna.2004.06.001.
10
Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries.中低收入国家心血管疾病一级预防的多重危险因素干预措施
Cochrane Database Syst Rev. 2015 Aug 4;2015(8):CD011163. doi: 10.1002/14651858.CD011163.pub2.

引用本文的文献

1
Catastrophic Health Expenditure and Its Determinants in Patients With Ischemic Heart Disease and Their Households: A Cross-Sectional Study From Iran in 2024.2024年伊朗的一项横断面研究:缺血性心脏病患者及其家庭的灾难性医疗支出及其决定因素
Health Sci Rep. 2025 Jul 20;8(7):e71082. doi: 10.1002/hsr2.71082. eCollection 2025 Jul.
2
The epidemiology and burden of cardiovascular diseases in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2021: findings from the Global Burden of Disease Study 2021.1990 - 2021年东南亚国家联盟(东盟)各国心血管疾病的流行病学与负担:全球疾病负担研究2021的结果
Lancet Public Health. 2025 Jun;10(6):e467-e479. doi: 10.1016/S2468-2667(25)00087-8.
3

本文引用的文献

1
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.发展中国家采用多药疗法预防心血管疾病:一项成本效益分析。
Lancet. 2006 Aug 19;368(9536):679-86. doi: 10.1016/S0140-6736(06)69252-0.
2
Advancement of global health: key messages from the Disease Control Priorities Project.全球卫生的进展:疾病控制优先项目的关键信息
Lancet. 2006 Apr 8;367(9517):1193-208. doi: 10.1016/S0140-6736(06)68440-7.
3
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Exploring the Involvement of New Members of the Interleukin Family in Cardiovascular Disease.
探索白细胞介素家族新成员在心血管疾病中的作用。
Curr Cardiol Rev. 2025;21(4):e1573403X330079. doi: 10.2174/011573403X330079241213071055.
4
Concurrent acute myocardial infarction and acute ischemic stroke in a diabetic patient undergoing chemotherapy for non-Hodgkin lymphoma: Should I administer thrombolytic therapy? A case report.一名正在接受非霍奇金淋巴瘤化疗的糖尿病患者并发急性心肌梗死和急性缺血性卒中:我应该给予溶栓治疗吗?一例病例报告。
Egypt Heart J. 2024 Dec 25;76(1):161. doi: 10.1186/s43044-024-00593-0.
5
Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.与2型糖尿病相关的心血管代谢危险因素:机制洞察
Clin Med Insights Endocrinol Diabetes. 2023 Dec 25;16:11795514231220780. doi: 10.1177/11795514231220780. eCollection 2023.
6
Physiotherapy-Led Health Promotion Strategies for People with or at Risk of Cardiovascular Diseases: A Scoping Review.物理治疗主导的心血管疾病患者或高危人群健康促进策略:系统评价。
Int J Environ Res Public Health. 2023 Nov 16;20(22):7073. doi: 10.3390/ijerph20227073.
7
Global Cardiovascular Research: Gaps and Opportunities.全球心血管研究:差距与机遇。
Curr Cardiol Rep. 2023 Dec;25(12):1831-1838. doi: 10.1007/s11886-023-01996-2. Epub 2023 Nov 20.
8
Peptidomimetics for CVD screened via TRADD-TRAF2 complex interface assessments.通过TRADD-TRAF2复合物界面评估筛选用于心血管疾病的拟肽
In Silico Pharmacol. 2023 Oct 27;11(1):28. doi: 10.1007/s40203-023-00166-0. eCollection 2023.
9
Rising prevalence, and improved but suboptimal management, of hypertension in South Africa: A comparison of two national surveys.南非高血压患病率上升且管理有所改善但仍未达最佳水平:两项全国性调查的比较
Glob Epidemiol. 2021 Sep 10;3:100063. doi: 10.1016/j.gloepi.2021.100063. eCollection 2021 Nov.
10
Hypoxia-associated genes predicting future risk of myocardial infarction: a GEO database-based study.预测心肌梗死未来风险的缺氧相关基因:一项基于GEO数据库的研究
Front Cardiovasc Med. 2023 Jul 3;10:1068782. doi: 10.3389/fcvm.2023.1068782. eCollection 2023.
《2006年心脏病和中风统计数据更新:美国心脏协会统计委员会及中风统计小组委员会报告》
Circulation. 2006 Feb 14;113(6):e85-151. doi: 10.1161/CIRCULATIONAHA.105.171600. Epub 2006 Jan 11.
4
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.南非高血压指南的成本效益分析:绝对风险与血压水平
Circulation. 2005 Dec 6;112(23):3569-76. doi: 10.1161/CIRCULATIONAHA.105.535922.
5
Cardiovascular disease in the developing world and its cost-effective management.发展中世界的心血管疾病及其成本效益管理。
Circulation. 2005 Dec 6;112(23):3547-53. doi: 10.1161/CIRCULATIONAHA.105.591792.
6
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).世界卫生组织心肌梗死和中风复发预防研究(WHO-PREMISE)。
Bull World Health Organ. 2005 Nov;83(11):820-9. Epub 2005 Nov 10.
7
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.β受体阻滞剂仍应作为原发性高血压治疗的首选药物吗?一项荟萃分析。
Lancet. 2005;366(9496):1545-53. doi: 10.1016/S0140-6736(05)67573-3.
8
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.根据个体的绝对心血管风险,使用药物降低血压和血液胆固醇。
Lancet. 2005;365(9457):434-41. doi: 10.1016/S0140-6736(05)17833-7.
9
Atenolol in hypertension: is it a wise choice?阿替洛尔用于治疗高血压:这是一个明智的选择吗?
Lancet. 2004;364(9446):1684-9. doi: 10.1016/S0140-6736(04)17355-8.
10
Old antihypertensives and new diabetes.老一代降压药与新型糖尿病
J Hypertens. 2004 Aug;22(8):1453-8. doi: 10.1097/01.hjh.0000133732.24501.9e.